Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149141 | 1.00 | KDM4E (0.32) | KDM4EALDH1A1ADORA2BADORA1CHEK1 | |
| SCHEMBL5150871 | 0.90 | ADORA2A (0.34) | KDM4EALDH1A1ADORA1ADORA2A | |
| SCHEMBL5150876 | 0.90 | ADORA2A (0.34) | KDM4EALDH1A1ADORA1ADORA2A | |
| SCHEMBL5152763 | 0.83 | ADORA2A (0.42) | ADORA2BADORA1ADORA2AKDM5B | |
| SCHEMBL5150681 | 0.81 | USP8 (0.34) | ALDH1A1 | |
| SCHEMBL5150678 | 0.81 | USP8 (0.34) | ALDH1A1 | |
| SCHEMBL5148909 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL5148911 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL5152899 | 0.74 | USP8 (0.40) | KDM4EALDH1A1ADORA1CHEK1ADORA2A | |
| SCHEMBL5151091 | 0.72 | ADORA2A (0.43) | KDM4EALDH1A1ADORA2BADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | KDM4E 3683/4885ALDH1A1 748/4885ADORA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.